Neural cell cultures to study spinal cord injury

Q3 Pharmacology, Toxicology and Pharmaceutics

Drug Discovery Today: Disease Models Pub Date : 2017-12-01 DOI:10.1016/j.ddmod.2018.10.005

George A. McCanney, Michael J. Whitehead, Michael A. McGrath, Susan L. Lindsay, Susan C. Barnett

{"title":"Neural cell cultures to study spinal cord injury","authors":"George A. McCanney, Michael J. Whitehead, Michael A. McGrath, Susan L. Lindsay, Susan C. Barnett","doi":"10.1016/j.ddmod.2018.10.005","DOIUrl":null,"url":null,"abstract":"<div><p>There are great challenges involved in identifying potential therapies for the repair of spinal cord injury (SCI). It is well accepted that not one, but a combination of therapeutic strategies will be required to effectively repair the damage. However, identifying novel therapeutics is hindered by the lack of reliable methods available that facilitate high throughput screening of numerous compounds. While the use of animals provides an important means for testing new therapies, <em>in vivo</em> models of SCI can be time consuming and require the use of large cohorts of animals. In this review, we have focused on three aspects of repair following SCI (1) neurite outgrowth, (2) glial scar and (3) remyelination. No <em>in vitro</em> model encapsulates all the features of SCI and we discuss the limitations and virtues of the various cultures, which range from individual cell-types through to complex co-cultures. We discuss how these cultures can be used as a moderate throughput screen to identify novel therapeutics for CNS repair before being verified in animal models.</p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2018.10.005","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Disease Models","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740675718300161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 4

Abstract

There are great challenges involved in identifying potential therapies for the repair of spinal cord injury (SCI). It is well accepted that not one, but a combination of therapeutic strategies will be required to effectively repair the damage. However, identifying novel therapeutics is hindered by the lack of reliable methods available that facilitate high throughput screening of numerous compounds. While the use of animals provides an important means for testing new therapies, in vivo models of SCI can be time consuming and require the use of large cohorts of animals. In this review, we have focused on three aspects of repair following SCI (1) neurite outgrowth, (2) glial scar and (3) remyelination. No in vitro model encapsulates all the features of SCI and we discuss the limitations and virtues of the various cultures, which range from individual cell-types through to complex co-cultures. We discuss how these cultures can be used as a moderate throughput screen to identify novel therapeutics for CNS repair before being verified in animal models.

Abstract Image

查看原文本刊更多论文

神经细胞培养研究脊髓损伤

寻找脊髓损伤(SCI)修复的潜在治疗方法是一个巨大的挑战。人们普遍认为，要有效地修复损伤，需要的不是一种治疗策略，而是多种治疗策略的结合。然而，由于缺乏可靠的方法来促进对许多化合物的高通量筛选，鉴定新的治疗方法受到阻碍。虽然使用动物为测试新疗法提供了重要手段，但脊髓损伤的体内模型可能是耗时的，并且需要使用大量动物。在这篇综述中，我们主要从三个方面探讨脊髓损伤后的修复(1)神经突生长，(2)神经胶质瘢痕和(3)髓鞘再生。没有一个体外模型囊括了SCI的所有特征，我们讨论了各种培养的局限性和优点，范围从单个细胞类型到复杂的共培养。我们讨论了在动物模型验证之前，如何将这些培养物用作中等通量筛选，以确定用于中枢神经系统修复的新疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today: Disease Models Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

自引率

0.00%

发文量

期刊介绍： Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.